Wagner K, Erhard J
Abteilung für Nieren- und Hochdruckkrankheiten, Universitätsklinikums der Gesamthochschule Essen.
Zentralbl Chir. 1992;117(12):648-52.
Immunosuppression after organ transplantation is based on pharmacologic interventions using steroids, azathioprin, sandimmun and anti-T-cell-globulins. During the induction-period the use of a high-dose combination-therapy guaranties a low incidence of rejection episodes. However infective complications may predominate. In the long-term phase the results of different immunosuppressive protocols are similar in respect to patient- and graft survival. This circumstance promotes the possibility to perform an individualised immunosuppression, which compiles to the personal demands of the graft recipient.
器官移植后的免疫抑制基于使用类固醇、硫唑嘌呤、环孢素和抗T细胞球蛋白的药物干预。在诱导期，使用高剂量联合疗法可确保排斥反应发生率较低。然而，感染性并发症可能占主导。在长期阶段，不同免疫抑制方案在患者和移植物存活方面的结果相似。这种情况增加了实施个体化免疫抑制的可能性，这符合移植物接受者的个人需求。
